Working… Menu

Inhibition of Aldosterone in Patients With Chronic Renal Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00430924
Recruitment Status : Completed
First Posted : February 2, 2007
Last Update Posted : February 8, 2012
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Lene Boesby, Herlev Hospital

Brief Summary:
The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.

Condition or disease Intervention/treatment Phase
Kidney Failure, Chronic Drug: Eplerenone Phase 4

Detailed Description:

Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy. It is accepted that proteinuria is a surrogate measurement for progression. If proteinuria can be lowered we hope to prolong patients pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this.

For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without. Blood pressures will be kept at the same level using other drugs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease
Study Start Date : March 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Drug: Eplerenone
Once daily administration for 8 weeks and 8 weeks control.

No Intervention: 2
Drug: Eplerenone
Once daily administration for 8 weeks and 8 weeks control.

Primary Outcome Measures :
  1. Proteinuria reduction [ Time Frame: bi-monthly ]

Secondary Outcome Measures :
  1. Evaluating blood pressure response and hyperkalaemia after aldosterone inhibition. [ Time Frame: weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Proteinuria > 500 mg/24 hours
  • Hypertension or anti-hypertensive treatment

Exclusion Criteria:

  • Diabetic nephropathy
  • GFR< 20 ml/min
  • P-potassium between 3,5 mmol/l and 5,0 mmol/l

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00430924

Layout table for location information
Rigshospitalet, Blegdamsvej 9
Copenhagen, Denmark, DK-2100 Ø
Herlev Hospital
Herlev, Denmark, DK-2730
Sponsors and Collaborators
Lene Boesby
Rigshospitalet, Denmark
Layout table for investigator information
Study Director: Svend Strandgaard, DMSc
Study Director: Anne-Lise Kamper, DMSc nonaffiliated
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lene Boesby, MD, Herlev Hospital Identifier: NCT00430924    
Other Study ID Numbers: B109LB1
First Posted: February 2, 2007    Key Record Dates
Last Update Posted: February 8, 2012
Last Verified: February 2012
Keywords provided by Lene Boesby, Herlev Hospital:
Kidney Failure, Chronic
Renin-Angiotensin System
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents
Antihypertensive Agents